Preliminary Evidence Suggests That a 12-Week Treatment with Tirzepatide Plus Low-Energy Ketogenic Therapy Is More Effective than Its Combination with a Low-Calorie Diet in Preserving Fat-Free Mass, Muscle Strength, and Resting Metabolic Rate in Patients with Obesity

生酮饮食 医学 无脂块 低热量 卡路里 内分泌学 肌肉团 内科学 脂肪团 体质指数 食品科学 癫痫 生物 精神科
作者
Luigi Schiavo,Biagio Santella,Monica Mingo,Gianluca Rossetti,Marcello Orio,Luigi Cobellis,Attilio Maurano,Antonio Iannelli,Vincenzo Pilone
出处
期刊:Nutrients [Multidisciplinary Digital Publishing Institute]
卷期号:17 (7): 1216-1216
标识
DOI:10.3390/nu17071216
摘要

Background: Tirzepatide (TZP), a unimolecular dual agonist targeting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, is a promising weight loss agent in obesity. The preservation of metabolically active fat-free mass (FFM), muscle strength (MS), and resting metabolic rate (RMR) is essential for optimizing fat mass (FM) reduction. Although TZP is typically combined with a low-calorie diet (LCD), its impact on FFM is uncertain, and studies on MS and RMR are lacking. Evidence suggests that Low-Energy Ketogenic Therapy (LEKT) may reduce FM while preserving FFM, MS, and RMR. Therefore, this study aimed to compare the effects of an LEKT and an LCD, both combined with TZP, on body weight (BW), FM, FFM, MS, and RMR in patients with obesity. Methods: We prospectively compared the effects of TZP combined with either an LCD or LEKT in 60 patients with obesity (n = 30 per group) over 12 weeks. BW, FM, FFM, MS, and RMR were measured at baseline and after 12 weeks. Clinical parameters, an assessment of dietary compliance, and side effects were also evaluated. Results: At 12-week follow-up, both groups showed a significant BW reduction from baseline (TZP+LEKT, p = 0.0289; TZP+LCD, p = 0.0278), with no significant intergroup difference (p = 0.665). Similarly, FM decreased significantly in both cohorts (TZP+LEKT, p < 0.001; TZP+LCD, p = 0.0185), with the TZP+LEKT group achieving a greater FM loss (p = 0.042). However, the TZP+LCD group exhibited significant declines from baseline in FFM (p = 0.0284), MS (p = 0.0341), and RMR (p < 0.001), whereas we did not observe any significant changes in FFM (p = 0.487), MS (p = 0.691), and RMR (p = 0.263) in the TZP+LEKT group. Intergroup direct comparisons confirmed that the TZP+LCD group experienced significantly greater reductions in FFM (p = 0.0388), MS (p = 0.046), and RMR (p = 0.019). Conclusions: Based on the findings of these preliminary data, we are able to support the hypothesis that TZP+LEKT seems to be superior to TZP+LCD in promoting FM reduction while preserving FFM, MS, and RMR in patients with obesity.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
健壮的大有完成签到 ,获得积分10
刚刚
奔向太阳完成签到,获得积分10
1秒前
酷波er的应助被wyr采纳,获得10
1秒前
木染发布了新的文献求助10
1秒前
cxcc完成签到,获得积分10
2秒前
天天向上的应助被zx采纳,获得10
2秒前
2秒前
2秒前
tian完成签到,获得积分10
2秒前
可爱的函函的应助被hub采纳,获得10
2秒前
2秒前
3秒前
Akim的应助被合适的铃铛采纳,获得10
3秒前
思源的应助被合适的铃铛采纳,获得10
3秒前
隐形曼青的应助被合适的铃铛采纳,获得10
3秒前
CipherSage的应助被zhuan采纳,获得10
4秒前
上官若男的应助被合适的铃铛采纳,获得10
4秒前
4秒前
曲奇饼干完成签到,获得积分20
4秒前
问题交给我你就闹心吧完成签到,获得积分10
5秒前
6秒前
6秒前
酷波er的应助被科研通管家采纳,获得10
6秒前
大模型的应助被科研通管家采纳,获得10
6秒前
6秒前
小蘑菇的应助被科研通管家采纳,获得10
6秒前
6秒前
充电宝的应助被科研通管家采纳,获得10
6秒前
Owen的应助被科研通管家采纳,获得10
6秒前
JamesPei的应助被科研通管家采纳,获得10
7秒前
molihuakai的应助被科研通管家采纳,获得10
7秒前
7秒前
华仔的应助被科研通管家采纳,获得10
7秒前
7秒前
电风扇完成签到,获得积分10
7秒前
小马甲的应助被科研通管家采纳,获得10
7秒前
dyf666666发布了新的文献求助10
7秒前
Hello的应助被科研通管家采纳,获得10
7秒前
思源的应助被科研通管家采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178375
求助须知:如何正确求助?哪些是违规求助? 9569182
关于积分的说明 21802781
捐赠科研通 7773247
什么是DOI,文献DOI怎么找? 3432799
关于科研通互助平台的介绍 2556793
邀请新用户注册赠送积分活动 2478346